Embolie Pulmonaire chez une Patiente Souffrant de la Maladie de Cushing : à propos d’un Cas
DOI:
https://doi.org/10.5281/hra.v2i3.5414Keywords:
Cushing's disease,, pulmonary embolismAbstract
RÉSUMÉ
L’exposition chronique aux glucocorticoïdes endogène entraine plusieurs complications. Elle est associée à une morbi mortalité cinq fois plus élevée comparée à la population générale en raison des complications cardiovasculaires qui lui sont associées. L’augmentation de l’incidence (12,9 % par personne-année) de la maladie thrombo embolique veineuse chez les patients souffrant de la maladie ou syndrome de cushing a été rapportée par plusieurs auteurs, due à l’exposition chronique aux glucocorticoïdes qui altèrent l’hémostase.
ABSTRACT
Chronic exposure to endogenous glucocorticoids leads to several complications. It is associated with five times higher morbidity and mortality compared to the general population due to the cardiovascular complications associated with it. The increased incidence (12.9% per person-year) of venous thromboembolism in patients suffering from Cushing's disease or syndrome has been reported by several authors, due to chronic exposure to glucocorticoids which impair hemostasis.
References
Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The Diagnosis of Cushing’s Syndrom : An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40.
Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. The Lancet. 2015 29;386(9996):913–27.
Koraćević G, Stojanović M, Petrović S, Simić D, Sakač D, Vlajković M, et al. CUSHING’S SYNDROME, A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IS A CANDIDATE FOR GUIDELINES. Acta Endocrinol Buchar. 2020;16(2):123–8.
Giordano R, Picu A, Marinazzo E, D’Angelo V, Berardelli R, Karamouzis I, et al. Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf). 2011 ;75(3):354–60.
Pathogenesis of vascular complications in Cushing’s syndrome | SpringerLink [Internet]. [cited 2023 Aug 19]. Available from: https://link.springer.com/article/10.1007/BF03401535
Sjöberg HE, Blombäck M, Granberg PO. Thromboembolic Complications, Heparin Treatment and Increase in Coagulation Factors in Cushing’s Syndrome. Acta Med Scand. 1976;199(1–6):95–8.
Stuijver DJF, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, et al. Incidence of Venous Thromboembolism in Patients with Cushing’s Syndrome: A Multicenter Cohort Study. J Clin Endocrinol Metab. 2011;96(11):3525–32.
Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, et al. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery. Eur J Endocrinol. 2010;163(5):783–91.
Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, et al. Anticoagulant Prophylaxis Markedly Reduces Thromboembolic Complications in Cushing’s Syndrome. J Clin Endocrinol Metab. 2002;87(8):3662–6.
Wagner J, Langlois F, Lim DST, McCartney S, Fleseriu M. Hypercoagulability and Risk of Venous Thromboembolic Events in Endogenous Cushing’s Syndrome: A Systematic Meta-Analysis. Front Endocrinol [Internet]. 2019 [cited 2023 Aug 17];9. Available from: https://www.frontiersin.org/articles/10.3389/fendo.2018.00805
Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler M (Th) B, Fliers E, et al. Hypercoagulable State in Cushing’s Syndrome: A Systematic Review. J Clin Endocrinol Metab. 2009;94(8):2743–50.
van der Pas R, de Bruin C, Leebeek FWG, de Maat MPM, Rijken DC, Pereira AM, et al. The Hypercoagulable State in Cushing’s Disease Is Associated with Increased Levels of Procoagulant Factors and Impaired Fibrinolysis, But Is Not Reversible after Short-Term Biochemical Remission Induced by Medical Therapy. J Clin Endocrinol Metab. 2012;97(4):1303–10.
van Haalen FM, Kaya M, Pelsma ICM, Dekkers OM, Biermasz NR, Cannegieter SC, et al. Current clinical practice for thromboprophylaxis management in patients with Cushing’s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN). Orphanet J Rare Dis. 2022;17(1):178.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC BY-NC-ND 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work